Progress Towards Prediction of Human Pharmacokinetic Parameters from In Vitro Technologies

References

• Atkins W. M., Lu W. D., Cook D. L. Is there a toxicological advantage for nonhyperbolic kinetics in cytochrome P450 catalysis?. J. Biol. Chem. 2002; 277: 33258–33266
   PubMed Web of Science ®Google Scholar
• Davis J. D., Aarons L., Houston J. B. Relationship between enoxacin and ciprofloxacin plasma concentrations and theophylline disposition. Pharm. Res. 1994; 11: 1424–1428
   PubMed Web of Science ®Google Scholar
• Davit B., Reynolds K., Yuan R., Ajayi F., Conner D., Fadiran E., Gillespie B., Sahajwalla C., Huang S. M., Lesko L. J. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug–drug interactions: impact on labeling. J. Clin. Pharmacol. 1999; 39: 899–910
   PubMed Web of Science ®Google Scholar
• Domanski T. L., HE Y.-A., Khan K. K., Roussel F., Wang Q., Halpert J. R. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 2001; 40: 10150–10160
   PubMed Web of Science ®Google Scholar
• Egnell A.-C., Houston J. B., Boyer S. In vivo heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine cooperativity. J. Pharmacol. Exp. Ther. 2003; 305: 1251–1262
   PubMed Web of Science ®Google Scholar
• Ervine C. M., Matthew D. E., Brennan B., Jezequel S. G., Humphrey M. J., Houston J. B. Comparison of the steady-state pharmacokinetics of fluconazole and ketoconazole and their relative effects on cytochrome P450 activity in rats: use of antipyrine and a steady-state infusion approach to assess plasma concentration-response relationships. Drug Metab. Dispos. 1996; 24: 211–215
   PubMed Web of Science ®Google Scholar
• Galetin A., Clarke S. E., Houston J. B. Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab. Dispos. 2002; 30: 1512–1522
   PubMed Web of Science ®Google Scholar
• Galetin A., Clarke S. E., Houston J. B. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone and nifedipine. Drug Metab. Dispos. 2003; 31: 1108–1116
   PubMed Web of Science ®Google Scholar
• He Y. A., Roussel F., Halpert J. R. Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch. Biochem. Biophys. 2003; 409: 92–101
   PubMed Web of Science ®Google Scholar
• Hosea N. A., Miller G. P., Guengerich F. P. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 2000; 39: 5929–5939
   PubMed Web of Science ®Google Scholar
• Houston J. B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 1994; 47: 1469–1479
   PubMed Web of Science ®Google Scholar
• Houston J. B., Carlile D. J. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab. Rev. 1997; 29: 891–922
   PubMed Web of Science ®Google Scholar
• Houston J. B., Kenworthy K. E. In vitro–in vivo scaling of CYP kinetic data not consistent with the classical Michaelis–Menten model. Drug Metab. Dispos. 2000; 28: 246–254
   PubMed Web of Science ®Google Scholar
• Houston J. B., Kenworthy K. E., Galetin A. Typical and atypical enzyme kinetics. Drug Metabolizing Enzymes: Cytochome P450 and Other Enzymes in Drug Discovery and Development, M. Fisher, J. Lee, S. Obach. FontisMedia, Lausanne 2003; pp. 211–254
   Google Scholar
• Hutzler J. M., Frye R. F., Korzekwa K. R., Branch R. A., Huang S.-M., Tracy T. S. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur. J. Pharm. Sci. 2001a; 14: 47–52
   PubMed Web of Science ®Google Scholar
• Hutzler J. M., Hauer M. J., Tracy T. S. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab. Dispos. 2001b; 29: 1029–1034
   PubMed Web of Science ®Google Scholar
• Ito K., Houston J. B. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes, (In press)
   Google Scholar
• Ito K., Houston J. B. Prediction of human drug clearance from in vitro and preclinical data using physiologically-based and empirical approaches, (In press)
   Google Scholar
• Ito K., Brown H. S., Houston J. B. Database analyses for the prediction of in vivo drug–drug interactions from in vitro data, (In press)
   Google Scholar
• Ito K., Iwatsubo T., Kanamitsu S., Ueda K., Suzuki H., Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug–drug interactions: metabolic interaction in the liver. Pharmacol. Rev. 1998; 50: 387–411
   PubMed Web of Science ®Google Scholar
• Ito K., Chiba K., Horikawa M., Ishugami M., Mizuno N., Aoki J., Gotoh Y., Iwatsubo T., Kanamitsu S., Kato M., Kawahara I., Niinuma K., Nishino A., Sato N., Tsukamoto Y., Ueda K., Itoh T., Sugiyama Y. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?. AAPS Pharm. Sci. 2002; 4(article 25)
   PubMedGoogle Scholar
• Iwatsubo T., Hirota N., Ooie T., Suzuki H., Shimada N., Chiba K., Ishizaki T., Green C. E., Tyson C. A., Sugiyama Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 1997; 73: 147–171
   PubMed Web of Science ®Google Scholar
• Kanamitsu S., Ito K., Sugiyama Y. Quantitative prediction of in vivo drug–drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm. Res. 2000; 17: 336–343
   PubMed Web of Science ®Google Scholar
• Kenworthy K. E., Clarke S. E., Andrews J., Houston J. B. Multi-site kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos. 2001; 29: 1–8
   PubMedGoogle Scholar
• Korzekwa K. R., Krishnamachary N., Shou M., Ogai A., Parise R. A., Rettie A. E., Gonzalez F. J., Tracy T. S. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998; 37: 4137–4147
   PubMed Web of Science ®Google Scholar
• Lin J. H. Sense and nonsense in the prediction of drug–drug inter-actions. Curr. Drug Metab. 2000; 1: 305–331
   PubMed Web of Science ®Google Scholar
• Lin J. H., Lu A. Y. H. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 1997; 49: 403–449
   PubMed Web of Science ®Google Scholar
• Lu P., Lin Y., Rodrigues A. D., Rushmore T. H., Baillie T. A., Shou M. Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4. Drug Metab. Dispos. 2001; 29: 1473–1479
   PubMed Web of Science ®Google Scholar
• Mahmood I., Balian J. D. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 1996; 9: 887–895
   Google Scholar
• Naritomi Y., Terashita S., Kimura S., Suzuki A., Kagayama A., Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 2001; 29: 1316–1324
   PubMed Web of Science ®Google Scholar
• Ngui J. S., Tang W., Stearns R. A., Shou M., Miller R. R., Zhang Y., Lin J. H., Baillie T. A. Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab. Dispos. 2000; 28: 1043–1050
   PubMed Web of Science ®Google Scholar
• Ngui J. S., Chen Q., Shou M., Wang R. W., Stearns R. A., Baillie T. A., Tang W. In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′- and 10-hydroxywarfarin. Drug. Met. Dispos. 2001; 29: 877–886
   PubMed Web of Science ®Google Scholar
• Obach R. S., Baxter J. G., Liston T. E., Silber B. M., Jones B. C., MacIntyre F., Rance D. J., Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 1997; 283: 46–58
   PubMed Web of Science ®Google Scholar
• Rodrigues A. D., Winchell G. A., Dobrinska M. R. Use of in vitro drug metabolism data to evaluate metabolic drug–drug interactions in man: the need for quantitative databases. J. Clin. Pharmacol. 2001; 41: 368–373
   PubMed Web of Science ®Google Scholar
• Segel I. H. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State enzyme Systems. Wiley & Sons Inc., New York 1975
   Google Scholar
• Shou M., Dai R., Cui D., Korzekwa K. R., Baillie T. A., Rushmore T. H. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J. Biol. Chem. 2001b; 276: 2256–2262
   PubMed Web of Science ®Google Scholar
• Shou M., Lin Y., Lu P., Tang C., Mei Q., Cui D., Tang W., Ngui J. S., Lin C. C., Singh R., Wong B. K., Yergey J. A., Lin J. H., Pearson P. G., Baillie T. A., Rodrigues A. D., Rushmore T. H. Enzyme kinetics of cytochrome P450-mediated reactions. Curr. Drug Metab. 2001a; 2: 17–36
   PubMed Web of Science ®Google Scholar
• Stone A. N., Mackenzie P. I., Galetin A., Houston J. B., Miners J. O. Isoform-selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab. Dispos. 2003; 31: 1086–1089
   PubMed Web of Science ®Google Scholar
• Tang W., Stearns R. A. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug–drug interactions. Curr. Drug Metab. 2001; 2: 185–198
   PubMed Web of Science ®Google Scholar
• Tang W., Stearns R. A., Kwei G. Y., Iliff S. A., Miller R. R., Egan M. A., Yu N. X., Dean D. C., Kumar S., Shou M., Lin J. H., Baillie T. A. Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J. Pharmacol. Exp. Ther. 1999; 291: 1068–1074
   PubMed Web of Science ®Google Scholar
• Tucker G. T., Houston J. B., Huang S.-M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—toward a consensus. Clin. Pharmacol. Ther. 2001; 70: 103–114
   PubMedGoogle Scholar
• von Moltke L. L., Greenblatt D. J., Cotreau-Bibbo M. M., Duan S. X., Harmatz J. S., Shader R. I. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J. Pharmacol. Exp. Ther. 1994; 268: 1278–1283
   PubMed Web of Science ®Google Scholar
• Wang R. W., Newton D. J., Liu N., Atkins W. M., Lu A. Y. H. Human cytochrome P-450 3A4: in vitro drug–drug interaction patterns are substrate-dependent. Drug Metab. Dispos. 2000; 28: 360–366
   PubMed Web of Science ®Google Scholar
• Williams J. A., Ring B. J., Cantrell V. E., Campanelle K., Jones D. R., Hall S. D., Wrighton S. A. Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab. Dispos. 2001; 30: 1266–1273
   Web of Science ®Google Scholar
• Witherow L. Y., Houston J. B. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J. Pharmacol. Exp. Ther. 1999; 290: 58–65
   PubMed Web of Science ®Google Scholar
• Yao C., Levy R. H. Inhibition-based metabolic drug–drug interactions: predictions from in vitro data. J. Pharm. Sci. 2002; 91: 1923–1935
   PubMed Web of Science ®Google Scholar
• Zomorodi K., Houston J. B. Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. Pharm. Res. 1995; 12: 1642–1646
   PubMed Web of Science ®Google Scholar
• Zuegge J., Schneider G., Coassolo P., Lave T. Prediction of hepatic metabolic clearance: comparison and assessment of prediction models. Clin. Pharmacokin. 2001; 40: 553–563
   PubMed Web of Science ®Google Scholar